Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 28, 2015 6:31 PM ET

Healthcare Equipment and Supplies

Company Overview of Eckert & Ziegler Radiopharma Gmbh

Company Overview

Eckert & Ziegler Radiopharma Gmbh manufactures imaging products used for diagnosis and treatment of cancer. The company develops molecular imaging equipment. Eckert & Ziegler Radiopharma Gmbh was formerly known as Eckert & Ziegler Medizintechnik GmbH. The company was founded in 2005 and is based in Berlin, Germany. The company operates as a subsidiary of Eckert & Ziegler Strahlen & Medizintechnik AG.

Robert-Rössle-Straße 10

Berlin,  13125

Germany

Founded in 2005

Phone:

49 30 94 10 84 280

Fax:

49 30 94 10 84 470

Key Executives for Eckert & Ziegler Radiopharma Gmbh

Eckert & Ziegler Radiopharma Gmbh does not have any Key Executives recorded.

Eckert & Ziegler Radiopharma Gmbh Key Developments

Eckert & Ziegler Radiopharma Gmbh Receives Recommendation from the European Medicines Agency for Approval of Pharmaceutical (68) Ge/(68) Ga Generators

Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its pharmaceutical (68) Ge/(68) Ga generators. This achievement marks the conclusion of a comprehensive decentralized evaluation procedure and the first time a gallium generator has been approved for the clinical development of highly specific diagnostic agents. Approval for sale in the respective countries is expected within the next one to two months. Gallium generators provide an inexpensive alternative for radiolabeling diagnostic probes using positron emission tomography (PET), an imaging process that can be used to determine whether tissue is diseased. The process is mainly used in cancer treatment. Until now, fluorine-18 or carbon-11 PET radioisotopes have usually been used to radiolabel diagnostic probes; these radioisotopes are produced using cyclotrons that are capitally intensive, large-scale dedicated installations requiring millions in investment. In contrast, the gallium generator is approximately the size of a thermos and can be sourced for far less money, lowering costs and increasing flexibility at nuclear medicine clinics. Once it has received approval, Eckert & Ziegler will also submit its documents to the U.S. Food and Drug Administration (FDA), establishing a Drug Master File with the agency. This will allow parties interested in developing new drugs to refer to the dossier and use the generator in clinical tests of medications and in other settings.

Similar Private Companies By Industry

Company Name Region
GME German Medical Engineering GmbH Europe
Dynabyte Informationssysteme GmbH Europe
Simag GmbH Europe
NiGuRa Metzler Optics International GmbH Europe
enverdis GmbH Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 19, 2015
OctreoPharm Sciences GmbH
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eckert & Ziegler Radiopharma Gmbh, please visit www.ezag.com/home/products/radiopharma.html. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.